Form 4: Boston Scientific Executive Acquires Stock Options and Restricted Stock Units

Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific, reports acquisition of stock options and restricted stock units.

Summary

• On March 1, 2024, Emily Woodworth, SVP, Global Controller and CAO of Boston Scientific, acquired 3,351 restricted stock units and 3,421 stock options.
• The restricted stock units will vest in four equal annual installments starting March 1, 2025, and each unit represents one share of Boston Scientific common stock.
• The stock options, with an exercise price of $67.13, also vest in four equal annual installments beginning March 1, 2025, and expire on March 1, 2034.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive as it reflects standard executive compensation practices, aligning executive interests with shareholder value. There are no indications of negative events or concerns.

Positives

• The acquisition of stock options and restricted stock units aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Industry Context

This is a standard practice for publicly traded companies to incentivize and retain key executives.

Comparison to Industry Standards

• Granting stock options and restricted stock units is a common practice among publicly traded companies, particularly in the healthcare and technology sectors.
• Companies like Medtronic, Abbott, and Johnson & Johnson also utilize similar equity-based compensation plans for their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to ensure long-term commitment and performance.

Stakeholder Impact

• The acquisition of stock options and restricted stock units by a key executive can positively influence shareholder confidence.
• It incentivizes the executive to work towards increasing the company's value, benefiting shareholders in the long run.

Key Dates